We can’t show the full text here under this license. Use the link below to read it at the source.
Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
Immune control and tumor environment in cancer treatments targeting PD-1/PDL-1 and CTLA-4: A research overview
AI simplified
Abstract
A total of 4,778 publications were reviewed, revealing a significant increase in research on tumor immune evasion from 1999 to 2022.
- Bladder cancer was identified as a particularly prominent focus in the literature on immune evasion.
- China, the USA, and Japan were the leading countries contributing to this body of research.
- Major institutions included MD Anderson Cancer Center, Harvard Medical School, Fudan University, and Sun Yat Sen University.
- Key journals in the field featured Frontiers in Immunology, Cancers, and Frontiers in Oncology.
- Ehen LP and Wang W were noted as prolific authors, while Topalian SL was one of the most cited figures.
- Current research trends are increasingly addressing challenges such as immunotherapy resistance and the complex signaling pathways involved.
AI simplified
Key numbers
1200
Publications by 2023
Anticipated number of articles published in 2023
1801 of 4778
Top contributing country
Publications from China related to anti-CTLA-4 and anti-PD-1 therapies
190935
Total citations by USA
Total citations for publications from the USA